Evolyra Therapeutics

Evolyra Therapeutics develops next-generation AAV gene therapies for limb-girdle muscular dystrophy and other rare neuromuscular diseases.

Health and bio

Evolyra Therapeutics has no funding amount on record yet; its latest known round is Seed (Apr 2026). Recent Funding first saw it on October 2, 2026.

Founders and team

• EC
  Ellie Carrell Founder

  source: crunchbase.com
• KP
  Kevin Passarello Founder

  source: crunchbase.com
• MH
  Melissa Hale Founder

  source: crunchbase.com
• NJ
  Nicholas Johnson Founder

  source: crunchbase.com

Raise history

1. April 1, 2026
   Seed · amount undisclosed
   Source: crunchbase.com

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/evolyra-therapeutics.